Loading organizations...
§ Private Profile · Cambridge, MA, USA
A neuroscience clinical-stage company developing next-generation antidepressant treatments for patients with inadequate SSRI response.
Euthymics Bioscience is a clinical-stage neuroscience company developing next-generation antidepressant treatments, based in Cambridge, Massachusetts. The organization focuses on central nervous system therapeutics, specifically targeting adult patients with major depression who do not respond adequately to standard selective serotonin reuptake inhibitors. Their primary clinical program centers on advancing their lead drug candidate, EB-1010, designed to improve efficacy while simultaneously reducing common adverse side effects such as weight gain, sexual dysfunction, and cognitive impairment. To accelerate this clinical development pipeline, the enterprise acquired DOV Pharmaceutical and secured $24 million in Series A financing backed by a syndicate of institutional investors including Novartis Venture Funds. The executive management team brings extensive pharmaceutical industry experience, featuring former scientific and medical leadership from Eli Lilly and Company. Euthymics Bioscience was founded in 2009 by Anthony McKinney, Frank Bymaster, and Gary Tollefson.
Euthymics Bioscience has raised $28.0M across 2 funding rounds.
Euthymics Bioscience has raised $28.0M in total across 2 funding rounds.
Euthymics Bioscience has raised $28.0M across 2 funding rounds. Most recently, it raised $4.0M Series A Extension in March 2011.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Mar 9, 2011 | $4M Series A Plus | Novartis, Venture Investors | TIM Barberich, GBS Venture Partners, H&Q Healthcare Investors, H&Q Life Sciences Investors | Announced |
| Jul 22, 2010 | $24M Series A | Campbell Murray, Paul Weiss | Andrew Baker, Frank Gentile, State OF Wisconsin Investment Board | Announced |
Euthymics Bioscience has raised $28.0M in total across 2 funding rounds.
Euthymics Bioscience's investors include Novartis, Venture Investors, Tim Barberich, GBS Venture Partners, H&Q Healthcare Investors, H&Q Life Sciences Investors, Campbell Murray, Paul Weiss, Andrew Baker, Frank Gentile, State of Wisconsin Investment Board.